Ibio, inc. (IBIO)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Revenues

96

314

108

795

527

651

45

91

78

153

122

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

37

75

135

275

379

134

160

316

349

367

819

205

0

0

0

617

0

0

390

351

371

233

320

-

175

-

-

Operating expenses:
Research and development (related party of $0, $217, $97 and $761), net of grant income of $0, $0, $0 and $37, respectively

999

888

977

1,624

1,453

1,273

1,124

1,042

966

993

985

1,112

1,136

1,049

820

853

1,048

704

551

764

815

731

1,185

418

343

585

552

967

631

656

1,177

1,054

1,307

1,162

1,456

1,169

1,137

619

157

Research and development - effect of Settlement Agreement (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-1,041

0

0

0

0

-

-

-

-

-

-

-

-

General and administrative (related party of $316, $288, $941 and $860)

3,161

2,581

2,986

3,224

2,844

3,393

2,871

2,995

2,605

2,587

2,498

2,894

2,837

2,351

2,469

2,176

2,403

1,684

1,422

1,448

1,222

1,302

1,050

937

951

1,051

949

952

1,229

1,039

1,023

1,442

1,246

1,745

1,188

2,704

1,927

1,245

1,213

General and administrative - effect of Settlement Agreement (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-700

0

0

0

0

-

-

-

-

-

-

-

-

Total operating expenses

4,160

3,469

3,963

4,848

4,297

4,666

3,995

4,037

3,571

3,580

3,483

4,006

3,973

3,400

3,289

3,029

3,451

2,388

1,973

2,212

2,037

2,033

2,235

1,355

1,294

1,636

-240

1,919

1,860

1,695

2,200

2,497

2,553

2,907

2,645

3,873

3,064

1,865

1,370

Operating loss

-4,064

-3,155

-3,855

-4,053

-3,770

-4,015

-3,950

-3,946

-3,493

-3,427

-3,361

-3,859

-3,936

-3,325

-3,154

-2,754

-3,072

-2,254

-1,813

-1,896

-1,688

-1,666

-1,416

-1,150

-1,294

-1,636

240

-1,302

-1,860

-1,695

-1,810

-2,146

-2,181

-2,673

-2,325

-3,529

-2,888

-1,865

-1,370

Other income (expense):
Interest expense - related party

616

615

620

474

474

476

476

478

478

479

480

482

481

483

483

484

323

0

0

-

0

-

-

-

-

-

-

43

15

17

15

18

17

16

9

16

7

12

13

Interest income

4

4

4

11

20

23

21

2

4

4

5

6

8

12

13

13

5

2

2

3

2

3

1

1

3

2

2

2

1

2

4

4

4

0

1

3

4

3

0

Royalty income

0

2

7

-

0

-2

6

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense - effect of Settlement Agreement (Note 8)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-122

0

0

0

0

-

-

-

-

-

-

-

-

Royalty income

-

-

-

-

-

-

-

4

4

2

9

5

4

4

12

4

5

6

6

8

9

10

5

8

9

10

15

12

7

4

11

2

14

5

11

8

4

3

6

Other income (expenses)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

-1

-

-

0

0

-

-

-

-

-

-

-

-

-

Change in fair value of warrant derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

109

635

-241

8,377

-918

-1,086

-2,704

1,951

-144

-2,839

-1,441

Total other income (expense)

-612

-609

-609

-451

-454

-455

-449

-472

-470

-473

-466

-471

-469

-467

-458

-467

-313

8

8

11

11

13

6

9

15

11

139

-

102

624

-

-2,867

-916

1,075

2,708

1,946

-142

-2,845

-1,447

Consolidated net loss

-4,676

-3,764

-4,500

-4,504

-4,224

-4,470

-4,399

-4,418

-3,963

-3,900

-3,827

-4,330

-4,405

-3,792

-3,612

-3,221

-3,385

-2,246

-1,805

-

-1,677

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to noncontrolling interest

0

-2

-1

-1

-1

-1

-1

0

-1

-1

-1

-1

-492

-563

-551

-544

-349

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income (loss) before provision for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,817

Net loss attributable to iBio, Inc.

-4,676

-3,762

-4,463

-4,503

-4,223

-4,469

-4,398

-4,418

-3,962

-3,899

-3,826

-4,329

-3,913

-3,229

-3,061

-2,677

-3,036

-2,246

-1,805

-1,885

-1,677

-1,653

-1,410

-1,141

-1,279

-1,625

379

-1,318

-1,758

-1,071

-2,051

-1,362

-3,098

-1,597

383

-1,582

-3,031

-4,710

-2,817

Deemed dividends - down round of Series A Preferred and Series B Preferred

0

21,560

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock dividends- iBio CMO Preferred Tracking Stock

65

65

66

65

64

65

66

65

64

65

66

64

26

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss available to iBio, Inc.

-4,741

-25,387

-4,529

-4,568

-4,287

-4,534

-4,464

-4,483

-4,026

-3,964

-3,892

-4,393

-3,939

-3,229

-3,061

-

-3,036

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss:
Consolidated net loss

-4,676

-3,764

-4,500

-4,504

-4,224

-4,470

-4,399

-4,418

-3,963

-3,900

-3,827

-4,330

-4,405

-3,792

-3,612

-3,221

-3,385

-2,246

-1,805

-

-1,677

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-4,676

-3,762

-4,463

-4,503

-4,223

-4,469

-4,398

-4,418

-3,962

-3,899

-3,826

-4,329

-3,913

-3,229

-3,061

-

-3,036

-

-

-1,885

-1,677

-1,653

-1,410

-1,141

-1,279

-1,625

379

-1,318

-1,758

-1,071

-2,051

-1,362

-3,098

-1,597

383

-1,582

-3,031

-4,710

-2,817

Other comprehensive loss - foreign currency translation adjustments

-2

1

-1

0

-1

1

-1

-1

0

0

0

-

-

0

0

2

2

1

-9

1

-12

-11

-3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency translation adjustments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-4,677

-3,764

-4,465

-4,505

-4,224

-4,469

-4,400

-4,419

-3,963

-3,900

-3,827

-

-

-3,792

-3,612

-3,219

-3,383

-2,245

-1,814

-1,884

-1,689

-1,664

-1,413

-1,141

-1,279

-1,625

379

-

-

-

-

-

-

-

-

-

-

-

-

Loss per common share attributable to iBio, Inc. stockholders - basic and diluted

-0.06

-0.69

-0.21

-0.23

-0.22

-0.24

-0.25

-0.36

-0.35

-0.41

-0.42

-1.53

-0.04

-0.04

-0.03

-0.03

-0.04

-0.03

-0.02

-0.03

-0.02

-0.02

-0.02

-

-0.02

-0.03

-

-

-0.04

-0.02

-

-0.03

-0.07

-0.05

0.01

-

-0.09

-0.15

-

Weighted-average common shares outstanding - basic and diluted

79

36

21

75,648

19

18

17

12,133

11,545

9,661

9,185

-231,683

89,109

89,109

89,109

88,101

81,158

77,326

77,307

76,175

72,989

70,957

65,859

-

65,642

63,984

-

-

47,767

47,767

-

-

45,715

32,382

-

-

32,338

-

-

(Loss) income per common share - basic (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.01

-

-

-

-0.04

-

-

-

-

-

-

-

-0.10

(Loss) income per common share - diluted (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.01

-

-

-

-0.04

-

-

-

-

-

-

-

-0.10

Weighted-average common shares outstanding - basic (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

56,692

-

-

-

47,767

-

-

-

32,382

-

-

-

28,272

Weighted-average common shares outstanding - diluted (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

60,626

-

-

-

47,767

-

-

-

34,670

-

-

-

28,272

Weighted average common shares outstanding - basic and diluted (in Shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,926

-